Apomorphine and ropinirole each keep a place in canine emesis

CURRENT FULL VERSION: A VetGirl continuing education podcast is drawing attention to a familiar but still unsettled question in small animal emergency care: when a dog needs emesis induction, is apomorphine or ropinirole the better choice? The timing is notable because ropinirole ophthalmic solution, sold as Clevor, became the first FDA-approved emetic for dogs in the U.S. in June 2020, giving clinicians an on-label alternative to the long-standing extra-label use of apomorphine. (fda.gov)

That regulatory shift changed the conversation, but not necessarily the day-to-day reality in practice. Apomorphine remains deeply embedded in emergency workflows because of its rapid onset and clinician familiarity. At the same time, ropinirole’s ophthalmic route offers a different kind of practicality: no injection is required, the product is labeled specifically for emesis induction in dogs, and FDA review established efficacy in a field study where 95% of treated dogs vomited within 30 minutes. Eighty-six percent responded after the first dose, and 14% required a second dose. (fda.gov)

Newer comparative evidence helps explain why both drugs are still in the conversation. In the 2025 Journal of Veterinary Emergency and Critical Care study discussed by VetGirl, investigators ran a prospective randomized clinical trial from October 2021 through March 2023 at 2 specialty referral hospitals, enrolling 132 client-owned dogs after suspected or confirmed ingestion of a toxin or foreign body. Dogs were randomized to receive topical ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs). If vomiting did not occur within 20 minutes, a second identical dose was given, and dogs were monitored for 40 minutes for emetic success, time to first emetic event, number of emetic events, and need for antiemetic rescue. The study population reflected common emergency presentations, including toxic foods such as chocolate, xylitol, grapes, and raisins; plants; medications; rodenticides and other poisons; foreign material; and cloth items such as socks, towels, and underwear. Dogs were excluded if they were younger than 4.5 months, weighed less than 1.8 kg, had ocular disease, CNS disease, hepatic disease, had already received antiemetics, or had ingested material for which emesis was contraindicated, including caustic or volatile substances.

A second 2025 Frontiers study using a blinded randomized crossover design in 24 healthy dogs likewise found ophthalmic ropinirole was equally effective overall compared with IV apomorphine for inducing emesis. The paper also summarized the pharmacologic distinction clearly: apomorphine is less selective, with activity beyond D2 receptors, while ropinirole is more D2-selective. That may matter clinically because apomorphine’s broader receptor activity has been associated with sedation, respiratory depression, hypotension, and tachycardia, whereas ropinirole’s adverse effects more commonly include ocular signs tied to topical administration. (pmc.ncbi.nlm.nih.gov)

The emergency-setting trial in client-owned dogs adds the practical nuance many clinicians care about most. Ropinirole and apomorphine showed similar efficacy for emesis induction, but apomorphine worked substantially faster: median time to first emetic event was 1.6 minutes with apomorphine versus 8.6 minutes with ropinirole. In the VetGirl summary, investigators had hypothesized that topical ropinirole would be equally effective as IV apomorphine but with fewer adverse effects, a framing that reflects why the comparison has become so clinically relevant now that ropinirole is the only FDA-approved veterinary emetic. That speed difference may not matter in every case, but in urgent toxicology or foreign-body presentations, it can influence how much gastric material is recovered and how quickly the team can move to the next step in care. (pubmed.ncbi.nlm.nih.gov)

Commentary from the University of Illinois College of Veterinary Medicine frames the decision in practical terms. Its pharmacy review notes that both agents are appropriate when emesis is indicated, but emphasizes that Clevor is FDA-approved for dogs 4.5 months and older weighing at least 1.8 kg, while apomorphine remains extra-label in the U.S. The same review also points out that apomorphine is considered a hazardous drug for handling purposes, an operational issue that can matter for hospital protocols, staff safety procedures, and inventory choices. (vetmed.illinois.edu)

Why it matters: For veterinary professionals, this is really a story about matching the drug to the case, not declaring a single winner. If a clinic values on-label use, avoids injectable administration when possible, or wants an option whose prolonged effects can be pharmacologically reversed with metoclopramide, ropinirole may be especially attractive. In the Reeves et al. protocol highlighted by VetGirl, metoclopramide was used as rescue after ropinirole and maropitant after apomorphine, underscoring that teams still need a plan for persistent vomiting after successful decontamination. If the priority is the fastest possible onset in a supervised hospital setting, apomorphine may still hold an advantage. Either way, current toxicology guidance continues to stress that emesis is only appropriate in selected patients, generally early after ingestion and only when the dog is neurologically appropriate and able to protect the airway. (pmc.ncbi.nlm.nih.gov)

The broader market context is also worth noting. While this story centers on emetics, antiemetic competition is also evolving. Dechra announced FDA approval of Emeprev, a bioequivalent injectable maropitant product for dogs and cats, in December 2025, with availability expected in early 2026. Additional product details suggest the launch may matter operationally as well as commercially: Emeprev contains benzyl alcohol, which Dechra says reduces injection pain in dogs compared with the pioneer product, and it does not require refrigeration, potentially simplifying storage and access in busy clinics. It is indicated for prevention and treatment of acute vomiting in dogs and for treatment of vomiting in cats, can be given SC or IV in adult animals, and is supplied as a 10 mg/mL solution in a 20 mL amber glass vial. (dechra-us.com)

What to watch: Watch for more head-to-head data in real-world toxicology and foreign-body cases, and for clinics to refine standing protocols around when to reach first for ophthalmic ropinirole, when to prioritize IV apomorphine, and when to skip emesis altogether in favor of other decontamination strategies. Just as importantly, watch how workflow details shape adoption: eligibility cutoffs, exclusion criteria, rescue antiemetic plans, handling precautions, and even storage and injection-comfort advantages in adjacent GI drugs are increasingly part of the decision-making landscape, not just raw efficacy. (pubmed.ncbi.nlm.nih.gov)